Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics Inc. has received FDA approval to lower the age eligibility for its Phase 3 HERO trial of ARD-101 in Prader Willi Syndrome (PWS) from 10 years to 7 years, thereby expanding the potential patient population and enhancing the competitive profile of the drug in the burgeoning PWS treatment landscape. The company is actively pursuing additional avenues to develop treatments for general obesity, positioning itself advantageously against conventional GLP-1 therapies, which, despite strong sales growth, present opportunities for innovative oral alternatives. Although the likelihood of success for ARD-101 has been revised to 50% and its potential launch delayed to 2029, the proactive adjustments in clinical trial criteria and ongoing communication from management indicate a strong commitment to advancing its drug development.

Bears say

Aardvark Therapeutics Inc faces significant uncertainties regarding the clinical trials for its lead candidate, ARD-101, with potential delays of 10 to 11 months in the HERO program timeline, compounded by unpredictable regulatory feedback. The risks outlined, including the possibility of negative clinical results, reliance on partnership developments, and untimely approvals, contribute to a cautious financial outlook. Additionally, concerns over the drug's efficacy and safety, along with potential dilution from financing activities, further exacerbate the negative sentiment towards the company's stock performance.

AARD has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 9 analysts, AARD has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.